共 48 条
[1]
Messina JP(2015)Global distribution and prevalence of hepatitis C virus genotypes Hepatology 61 77-87
[2]
Humphreys I(2014)Antiviral treatment of hepatitis C BMJ 7 g3308-1195
[3]
Flaxman A(2014)Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response Hepatology 60 1187-216
[4]
Feeney ER(2014)Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir Aliment Pharmacol Ther 39 209-573
[5]
Chung RT(2015)Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans Aliment Pharmacol Ther 42 559-1192
[6]
Bichoupan K(2014)New hepatitis C therapies: the toolbox, strategies and challenges Gastroenterology 146 1176-1869
[7]
Martel-Laferriere V(2015)Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease Hepatology 61 1860-954
[8]
Sachs D(2015)Diseases Society of America (AASLD/IDSA) HCV guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus Hepatology 62 932-1493
[9]
Bichoupan K(2014)Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 1483-1898
[10]
Schwartz JM(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-1888